ReviewWorld journal of cardiology2019
Percutaneous devices for left atrial appendage occlusion: A contemporary review.
Review in World journal of cardiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 33 citations in OpenAlex.
- Left atrial appendage anatomy: clinical implications for cardiac procedures.Anatomical science international · 2025Article
- Pericardial Tamponade After Left Atrial Appendage Occlusion Placement: A Case for Emergent Point-of-Care Ultrasound.Cureus · 2025Article
- The Left Atrial Appendage and Atrial Fibrillation-A Contemporary Review.Journal of clinical medicine · 2023Review
- Management of Left Atrial Appendage Perforation Complicated by Cardiac Tamponade during Left Atrial Appendage Occluder Device Deployment.Acta Cardiologica Sinica · 2023Article
- Strategies for surface coatings of implantable cardiac medical devices.Frontiers in bioengineering and biotechnology · 2023Review
- Effects of Left Atrial Appendage Closure on Neuroendocrine Function in Patients with Nonvalvular Atrial Fibrillation.Medical science monitor : international medical journal of experimental and clinical research · 2022Article
- National Yearly Trend of Utilization and Procedural Complication of the Watchman Device in the United States.Cureus · 2022Article
- Amulet™ Shines and Protects; Pacing Battle Intensifies with "More Leads or No Leads"?The Journal of innovations in cardiac rhythm management · 2022Article
- Left atrial appendage exclusion in atrial fibrillation.Frontiers in cardiovascular medicine · 2022Review
- Watchman outcomes comparing post-implantation anticoagulation with warfarin versus direct oral anticoagulants.Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · 2021Article
- Minimally invasive left atrial appendage (LAA) clip insertion after challenging LAA occluder implantation to minimize the risk of stroke.Journal of surgical case reports · 2020Article
- Left Atrial Appendage Occlusion: Current Stroke Prevention Strategies and a Shift Toward Data-Driven, Patient-Specific Approaches.Journal of the Society for Cardiovascular Angiography & InterventionsReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patient with atrial fibrillation (AF) are at risk of developing stroke with the left atrial appendage (LAA) being the most common site for thrombus formation. If left untreated, AF is associated with 4 to 5 folds increase in the risk of ischemic stroke in all age groups. About 5% to 15% of AF patients have atrial thrombi on transesophageal echocardiography, and 91% of those thrombi are located in the LAA in patient with nonrheumatic AF. Although oral anticoagulants are the gold-standard treatment for stroke prevention in patients with non-valvular AF, some patients are at high risk of bleeding and deemed not candidates for anticoagulation. Therefore, LAA occlusion (LAAO) has emerged as alternative approach for stroke prevention in those patients. Surgical LAAO is associated with high rate of unsuccessful closure and recommended only in patients with AF and undergoing cardiac surgery. Percutaneous LAAO uses transvenous access with trans-septal puncture and was first tested using the PLAATO device. Watchman is the most common and only Food and Drug Administration (FDA) approved device for LAAO. LAAO using Watchman device is non-inferior to warfarin therapy in preventing ischemic stroke/systemic thromboembolism. However, it is associated with lower rates of hemorrhagic stroke, bleeding and death. Amplatzer is another successful LAAO device that has CE mark and is waiting for FDA approval. Optimal antithrombotic therapy post LAAO is still under debate and highly patient-specific. The aim of this paper is to systematically review the current literature to evaluate the efficacy and safety of different LAAO devices.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.